Tekmira improves finances and enters the clinic
This article was originally published in Scrip
Executive Summary
The Canadian RNA interference (RNAi) company Tekmira Pharmaceuticals now believes it has sufficient funds to continue product development until mid-2011, owing to a development agreement with Roche that it signed in May.